Supplementary Material.pdf (491.75 kB)
Download fileSupplementary Material – PD-1 Targeted Immunotherapy For Advanced Hepatocellular Cancer: Current Utilization And Outcomes In The United States
dataset
posted on 2022-02-17, 10:00 authored by Figshare Future Science GroupFigshare Future Science Group, Johannes Uhlig, Stacey Stein, Hyun S. Kim|
Supplementary Material. PD-1 Targeted Immunotherapy For Advanced Hepatocellular Cancer: Current Utilization And Outcomes In The United States Supplemental Table 1: ICD 09 and ICD 10 codes used for abstraction of patient comorbidities. Supplemental Table 2: comorbidities of included patients. Supplemental Figure 1: proportion of advanced HCC receiving PD-1 IMT according to US geography. |
